All In Biotech

NDA 214510 · Mayne Pharma

Epsolay

Benzoyl Peroxide · Topical

Last checked: Nov 19, 2026Latest source record: Apr 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 22, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

162

44 Phase 3, 7 recruiting

FAERS reports

1,390

830 serious, 49 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 11, 2025.

EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. ( 1 )

Mechanism: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action in the treatment of rosacea is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EPSOLAY · BENZOYL PEROXIDE 5% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzoyl Peroxide" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective147
  • rash94
  • erythema83
  • pruritus77
  • off label use72
  • fatigue65
  • pain65
  • nausea64
  • acne60
  • anxiety60
  • depression54
  • dry skin46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
20054
20067
20076
200811
200911
201018
201123
201228
201332
201432
201547
201664
201763
201877
2019105
2020114
202195
2022108
2023175
2024138
2025126
202699

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epsolay (Benzoyl Peroxide)

2024 spending

$463K

Beneficiaries

444

845 claims

Per beneficiary

$1,042

$16.78 per unit

View as table
YearSpending
2020$0
2021$0
2022$130,315
2023$437,973
2024$462,534

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 363 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.